Report Highlights

China's Role in the Global Nutricosmetics Supply Chain

China occupies a dual position in the global nutricosmetics supply chain — simultaneously one of the world's largest consumers and a major upstream producer of key raw materials including hydrolyzed collagen peptides, hyaluronic acid, and botanical actives such as astaxanthin and coenzyme Q10. Domestic manufacturers like Bloomage Biotechnology supply hyaluronic acid to international brands across Japan, South Korea, and the European Union, making China structurally indispensable at the ingredient level even as finished product imports surge through cross-border channels. Annual hydrolyzed collagen peptide exports from Chinese processors exceed 120,000 metric tons, predominantly shipped to Southeast Asian markets and the United States.

On the import side, China draws heavily on Australian, Japanese, and South Korean finished nutricosmetic products, with Japan alone accounting for over USD 600 million in ingestible beauty imports annually via both general trade and the Tmall Global and JD Worldwide cross-border e-commerce platforms. South Korean brands leverage the cultural influence of K-beauty to position collagen drinks and skin-brightening supplements at premium price points targeting urban Chinese women aged 25 to 45. This dual role — raw material exporter and finished product importer — gives China's nutricosmetics supply chain a complexity that few other national markets can match, creating both arbitrage opportunities and structural trade imbalances that are increasingly attracting regulatory scrutiny from China's National Medical Products Administration.

Growth Drivers for China's Nutricosmetics Trade and Production

Three forces are expanding China's nutricosmetics production base and trade volume simultaneously. First, the post-pandemic acceleration of health consciousness among Chinese urban consumers has driven double-digit growth in ingestible collagen, with retail sales on Tmall and JD.com exceeding USD 1.8 billion in 2023 alone. Domestic manufacturers are responding by investing in GMP-certified production facilities — By-Health and Hansu Group each committed over RMB 500 million to capacity expansion between 2022 and 2024 — a capital commitment that signals a structural shift from import dependency toward domestic production self-sufficiency in key segments.

Second, China's booming live-stream commerce ecosystem, led by platforms including Douyin and Kuaishou, has created a high-velocity distribution channel that compresses the time from product launch to nationwide sales penetration to as little as 72 hours. This benefits domestic producers disproportionately, as they can navigate Douyin's promotional compliance requirements more efficiently than foreign brands managing cross-border regulatory filings. Third, government policy actively supports the domestic biotechnology inputs sector — the Ministry of Industry and Information Technology's 14th Five-Year Bioeconomy Plan designates hyaluronic acid and collagen peptide production as strategic industrial priorities, unlocking preferential land use rights, R&D tax credits, and export financing for qualifying manufacturers.

Supply Chain Risks and Trade Barriers

China's nutricosmetics supply chain carries three material risks. The most immediate is raw material concentration: marine collagen sourcing is geographically clustered around the Bohai Sea and East China Sea fishing zones, exposing the supply chain to seasonal catch restrictions and the environmental compliance crackdowns that the Ministry of Ecology and Environment has intensified since 2021. Any tightening of marine resource extraction quotas directly translates to input cost inflation for finished product manufacturers. A secondary risk is the NMPA's evolving definition of nutricosmetics — products making skin-improvement claims are increasingly assessed under the Blue Hat health food licensing framework, adding 18 to 24 months to product registration timelines for both domestic and imported SKUs.

Trade barrier exposure is equally significant. China's current import tariff on finished nutricosmetic supplements ranges from 10% to 20% depending on product classification, creating a meaningful landed-cost disadvantage for foreign brands competing against locally manufactured equivalents. Cross-border e-commerce channels under the CBEC regime offer tariff relief, but the NMPA's 2023 guidance requiring substantiated efficacy documentation for beauty-claim products applies to cross-border SKUs as well, partially closing the regulatory arbitrage window that foreign brands relied on through 2022. Currency risk further complicates the trade economics for importers, as RMB depreciation episodes directly inflate the cost of sourcing overseas finished goods priced in USD or JPY.

Trade and Investment Opportunities in China's Nutricosmetics Market

The clearest near-term trade opportunity lies in supplying high-purity bioactive ingredients to China's rapidly expanding domestic nutricosmetics manufacturers. Suppliers of New Zealand bovine collagen, Scandinavian marine collagen, and Japanese-grade hyaluronic acid face strong demand from Chinese contract manufacturers seeking ingredient diversification and traceability documentation to satisfy increasingly quality-conscious domestic consumers. Companies like Gelita AG and Nitta Gelatin are already expanding their sales presence in China, but significant white space remains for mid-tier European and Oceanian ingredient suppliers willing to pursue China FDA (NMPA) ingredient registration, a process that typically requires 12 to 18 months but delivers durable market access.

On the investment side, inbound FDI targeting contract manufacturing organizations in the Yangtze River Delta — particularly in Hangzhou and Suzhou — offers a structurally sound entry point. These locations combine pharmaceutical-grade manufacturing infrastructure, proximity to e-commerce distribution hubs in Shanghai, and local government incentives for health product investment. Additionally, Japan and Australia represent growing export destinations for Chinese-produced nutricosmetic ingredients, and Chinese manufacturers with internationally certified production facilities are positioned to capture incremental export revenue as global demand for cost-competitive collagen peptides and plant-based beauty actives expands. Investment in FSSC 22000 and ISO 22000-certified production lines directly unlocks export market access to the EU and the United States.

Market at a Glance

Leading Market Participants

• By-Health Co., Ltd.
• Bloomage Biotechnology Corporation
• Shiseido Company
• FANCL Corporation
• Swisse Wellness
• Herbalife Nutrition
• Hansu Group
• GNC Holdings
• Comvita Limited
• H&H Group (Biostime)

Regulatory and Trade Policy Environment

China's trade policy framework for nutricosmetics is defined primarily by NMPA regulations governing health food product registration, the Blue Hat licensing system, and the cross-border e-commerce (CBEC) tariff regime administered by the General Administration of Customs. Under CBEC rules, individual transaction limits of RMB 5,000 and an annual personal limit of RMB 26,000 apply to imported nutricosmetic purchases, providing a meaningful volume channel for foreign brands that have not yet completed full NMPA registration. The Regional Comprehensive Economic Partnership (RCEP), effective in China since January 2022, has reduced import tariffs on nutricosmetic ingredients and finished goods sourced from Japan, South Korea, Australia, and New Zealand, meaningfully improving landed-cost economics for these origin markets.

Domestically, the NMPA's 2021 revision to the Health Food Registration and Filing Management Measures tightened efficacy claim documentation requirements, requiring human clinical substantiation for skin-health claims — a standard that has disproportionately affected smaller domestic brands and new-entrant foreign SKUs. China's export regulatory framework for nutricosmetic ingredients is comparatively permissive, with hydrolyzed collagen and hyaluronic acid classified under standard food additive export categories requiring only standard customs declaration. However, the EU's Novel Food Regulation and the FDA's dietary supplement notification requirements create market-entry compliance costs for Chinese ingredient exporters targeting Western markets, partially constraining the export upside for producers not yet holding third-party international certifications.

China Nutricosmetics Supply Chain Outlook to 2032

By 2032, China's nutricosmetics supply chain will have shifted materially toward domestic finished-product self-sufficiency, driven by continued NMPA-registered capacity investment and the maturation of a domestic biotechnology inputs sector that currently supplies global ingredient markets. The share of total retail value captured by Chinese-origin brands is forecast to rise from approximately 45% in 2024 to over 60% by 2032, as companies including By-Health and Bloomage Biotechnology advance into finished consumer product categories currently dominated by Japanese and Australian imports. AI-driven personalized nutrition platforms are already enabling domestic brands to differentiate on formulation sophistication rather than country-of-origin premiums.

Trade flow shifts will be equally significant. China's export of finished nutricosmetic products — currently negligible beyond Southeast Asia — will expand into Middle Eastern and Central Asian markets, supported by the Belt and Road Initiative logistics infrastructure and halal-certified product development programs being piloted by Hansu Group and Infinitus. On the input side, Chinese processors will face increasing competition from Indian and Southeast Asian collagen producers as global brands seek geographic supply chain diversification. Manufacturers that invest in blockchain-enabled ingredient traceability and internationally recognized quality certifications before 2027 will secure defensible positions in both domestic and export markets through the forecast period.

Market Segmentation

By Product Type

• Collagen Supplements
• Hyaluronic Acid Products
• Vitamins and Antioxidants
• Botanical and Herbal Extracts
• Functional Beverages
• Others

By Form

• Tablets and Capsules
• Powder
• Liquid and Drinks
• Gummies and Soft Chews
• Others

By Distribution Channel

• E-Commerce (Tmall, JD.com, Douyin)
• Cross-Border E-Commerce (CBEC)
• Pharmacies and Drugstores
• Specialty Beauty Retailers
• Direct Sales
• Others

By End User

• Women (25–45 Age Group)
• Women (45+ Age Group)
• Men
• Teenagers
• Others

Frequently Asked Questions

Q1. What are the primary raw materials sourced domestically for China's nutricosmetics production? ▼

China domestically produces hyaluronic acid, hydrolyzed marine collagen peptides, astaxanthin, and coenzyme Q10 at commercial scale. Bloomage Biotechnology is the world's largest hyaluronic acid producer and supplies both domestic brands and international customers.

Q2. How do cross-border e-commerce regulations affect imported nutricosmetic brands in China? ▼

CBEC rules allow imported nutricosmetics to enter China under individual transaction and annual spending caps without full NMPA registration. However, the 2023 NMPA guidance on efficacy documentation now applies to CBEC SKUs making skin-improvement claims, reducing the prior regulatory advantage.

Q3. Which logistics corridors are most critical for nutricosmetic ingredient trade into China? ▼

The Port of Shanghai and Tianjin Port handle the majority of inbound nutricosmetic ingredient shipments, particularly from Japan, Australia, and New Zealand. Cold-chain logistics infrastructure connecting these ports to Yangtze River Delta manufacturing clusters is the most operationally critical link in the supply chain.

Q4. What is driving Chinese nutricosmetic ingredient exports to international markets? ▼

Cost-competitive hydrolyzed collagen peptides and pharmaceutical-grade hyaluronic acid from Chinese producers are the primary export drivers, shipped mainly to Southeast Asia, the United States, and the European Union. RCEP tariff reductions have further improved the price competitiveness of Chinese ingredients in member markets.

Q5. How will the NMPA's evolving regulatory framework affect market entry timelines to 2032? ▼

Increasing NMPA requirements for clinical efficacy substantiation will extend product registration timelines, particularly for foreign brands, from the current 18–24 months toward 30 months for complex formulations. Brands that pre-invest in China-compliant clinical trial programs before 2026 will hold a durable first-mover advantage in registered product categories.